HUP9902429A2 - TNF-receptor-asszociált faktor (TRAF) modulátorok előállítása és alkalmazása - Google Patents

TNF-receptor-asszociált faktor (TRAF) modulátorok előállítása és alkalmazása

Info

Publication number
HUP9902429A2
HUP9902429A2 HU9902429A HUP9902429A HUP9902429A2 HU P9902429 A2 HUP9902429 A2 HU P9902429A2 HU 9902429 A HU9902429 A HU 9902429A HU P9902429 A HUP9902429 A HU P9902429A HU P9902429 A2 HUP9902429 A2 HU P9902429A2
Authority
HU
Hungary
Prior art keywords
traf2
proteins
binding
dna sequences
traf
Prior art date
Application number
HU9902429A
Other languages
English (en)
Inventor
Mark Boldin
Andrei Kovalenko
Nikolai Malinin
Igor Mett
David Wallach
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11780096A external-priority patent/IL117800A0/xx
Priority claimed from IL11913396A external-priority patent/IL119133A0/xx
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of HUP9902429A2 publication Critical patent/HUP9902429A2/hu
Publication of HUP9902429A3 publication Critical patent/HUP9902429A3/hu
Publication of HU226328B1 publication Critical patent/HU226328B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát TRAF2-faktőrhőz kötődni képes prőteineket és azőkTRAF2-prőteinhez kötődni képes izőfőrmjait, analógjait vagyszármazékait kódőló DNS-szekvenciák képezik, valamint a találmányszerinti DNS-szekvenciák által kódőlt prőteinek, és azők TRAF2-prőteinhez kötődni képes izőfőrmjai, analógjai, fragmensei ésszármazékai, valamint az ellenük termeltetett ellenanyagők. Atalálmány tárgyát képezik a TRAF2-prőteinek általmódősítőtt/közvetített cellűláris hatásők módősítására alkalmasgyógyászati készítmények is, tővábbá a találmány szerinti prőteinek,DNS-szekvenciák, ellenanyagők és gyógyászati készítmények alkalmazása,NF-kB-indűkcióval és más, TRAF2-faktőr közvetítette aktivitássalkapcsőlatős kórős állapőt kezelésére. A találmány szerinti megőldásalkalmas TRAF2-faktőr közvetítette aktivitással kapcsőlatős kórősállapőtők kezelésére, megelőzésére. ŕ
HU9902429A 1996-04-02 1997-04-01 Modulators of tnf receptor associated factor (traf), their preparation and use HU226328B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11780096A IL117800A0 (en) 1996-04-02 1996-04-02 Modulators of TNF receptor associated factor (TRAF) their preparation and use
IL11913396A IL119133A0 (en) 1996-08-26 1996-08-26 Modulators of TNF receptor associated factor (TRAF) their preparation and use
PCT/IL1997/000117 WO1997037016A1 (en) 1996-04-02 1997-04-01 Modulators of tnf receptor associated factor (traf), their preparation and use

Publications (3)

Publication Number Publication Date
HUP9902429A2 true HUP9902429A2 (hu) 1999-10-28
HUP9902429A3 HUP9902429A3 (en) 2001-11-28
HU226328B1 HU226328B1 (en) 2008-09-29

Family

ID=26323248

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902429A HU226328B1 (en) 1996-04-02 1997-04-01 Modulators of tnf receptor associated factor (traf), their preparation and use

Country Status (23)

Country Link
US (2) US7485456B1 (hu)
EP (1) EP0894130B1 (hu)
JP (1) JP4180114B2 (hu)
CN (1) CN1197966C (hu)
AT (1) ATE380866T1 (hu)
AU (1) AU732793B2 (hu)
BG (1) BG64755B1 (hu)
BR (1) BR9708518A (hu)
CA (1) CA2250085C (hu)
CZ (3) CZ299094B6 (hu)
DE (1) DE69738370T2 (hu)
DK (1) DK0894130T3 (hu)
EA (1) EA004309B1 (hu)
EE (1) EE04783B1 (hu)
ES (1) ES2294796T3 (hu)
HK (1) HK1018910A1 (hu)
HU (1) HU226328B1 (hu)
NO (1) NO327054B1 (hu)
NZ (1) NZ331902A (hu)
PT (1) PT894130E (hu)
SK (3) SK287889B6 (hu)
UA (1) UA71889C2 (hu)
WO (1) WO1997037016A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
US5843721A (en) * 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
AU1390299A (en) * 1997-11-07 1999-05-31 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
AU2877899A (en) * 1998-02-27 1999-09-15 Regents Of The University Of California, The A novel inhibitor of the inflammatory response induced by tnfalpha and il-1
ES2251831T3 (es) 1998-05-06 2006-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Inhibidores de la activacion de nf-kb.
MXPA01001747A (es) * 1998-08-18 2003-06-06 Basf Ag Tpl-2/cot cinasa y metodos de uso.
IL131719A0 (en) * 1999-09-02 2001-03-19 Yeda Res & Dev Iren protein its preparation and use
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
KR20020069140A (ko) * 2001-02-21 2002-08-29 주식회사 코메드 종양 괴사 인자 수용체 관련 인자 6 억제 단백질
DE60213596T2 (de) 2001-06-22 2007-09-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Abin zum schutz gegen hepatitis
ES2415331T3 (es) * 2002-04-18 2013-07-25 Yeda Research And Development Co., Ltd. Derivados de la cadena gamma del receptor de IL-2, su preparación y su uso
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
PL1678209T3 (pl) * 2003-10-07 2011-09-30 Yeda Res & Dev Przeciwciała skierowane przeciwko NIK, ich wytwarzanie i zastosowanie
EP1689786B1 (en) * 2003-11-30 2014-05-14 Yeda Research And Development Co., Ltd. Methods and agents for immune modulation and methods for identifying immune modulators
IL173104A0 (en) * 2006-01-12 2006-06-11 Yeda Res & Dev Siva and ubiquintination
EP3629022A1 (en) 2008-07-25 2020-04-01 Richard W. Wagner Protein screening methods
GB201012420D0 (en) 2010-07-23 2010-09-08 Univ Erasmus Medical Ct Foetal heamoglobin inhibitor
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
CN105200073B (zh) * 2010-09-01 2019-03-01 山东新时代药业有限公司 人肿瘤坏死因子受体-Fc融合基因及其产物蛋白
TW201247650A (en) 2011-03-16 2012-12-01 Hoffmann La Roche 6,5-heterocyclic propargylic alcohol compounds and uses therefor
EP3357511B1 (en) 2011-06-30 2020-05-13 Genzyme Corporation Inhibitors of t-cell activation
ES2657743T3 (es) 2011-07-19 2018-03-06 Philogen S.P.A. Terapia secuencial con anti-CTLA-4 e IL-2 dirigida
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
CN105986001B (zh) * 2015-02-12 2019-12-03 上海交通大学 一种基于膜结合蛋白和荧光互补的高通量猎物拮抗剂筛选方法
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641876A (en) * 1990-01-05 1997-06-24 Cornell Research Foundation, Inc. Rice actin gene and promoter
CA2228039A1 (en) * 1995-08-02 1997-02-13 Teresa J. Ingram Composition for administration to patients with chronic fatigue syndrome and acquired immune deficiency syndrome
AU6692996A (en) 1995-08-08 1997-03-05 Tularik Inc. Inhibitors of apoptosis
US5804412A (en) * 1996-04-01 1998-09-08 The Regents Of The University Of California Nucleic acids encoding sorting nexins and methods of using same
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
BR9708918A (pt) 1996-05-08 1999-08-03 Henkel Corp Tensoativo processo para fabricar o mesmo produto e composição de limpeza
US5843721A (en) * 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein

Also Published As

Publication number Publication date
CZ299094B6 (cs) 2008-04-23
CN1221449A (zh) 1999-06-30
CN1197966C (zh) 2005-04-20
SK287085B6 (sk) 2009-11-05
JP2000507826A (ja) 2000-06-27
EA004309B1 (ru) 2004-02-26
DE69738370D1 (de) 2008-01-24
PT894130E (pt) 2008-01-14
AU2175597A (en) 1997-10-22
CZ298866B6 (cs) 2008-02-27
BG102817A (en) 1999-05-31
US8236507B2 (en) 2012-08-07
EA199800885A1 (ru) 1999-04-29
US7485456B1 (en) 2009-02-03
NZ331902A (en) 2000-02-28
CA2250085A1 (en) 1997-10-09
EE04783B1 (et) 2007-02-15
JP4180114B2 (ja) 2008-11-12
CA2250085C (en) 2009-10-20
BG64755B1 (bg) 2006-02-28
DE69738370T2 (de) 2008-12-04
AU732793B2 (en) 2001-05-03
ATE380866T1 (de) 2007-12-15
EP0894130A1 (en) 1999-02-03
EE9800322A (et) 1999-04-15
ES2294796T3 (es) 2008-04-01
HU226328B1 (en) 2008-09-29
BR9708518A (pt) 1999-08-03
CZ318398A3 (cs) 1999-05-12
NO984551L (no) 1998-11-24
NO984551D0 (no) 1998-09-29
SK287890B6 (sk) 2012-03-02
WO1997037016A1 (en) 1997-10-09
SK136198A3 (en) 1999-05-07
HUP9902429A3 (en) 2001-11-28
SK287889B6 (sk) 2012-03-02
NO327054B1 (no) 2009-04-14
UA71889C2 (uk) 2005-01-17
HK1018910A1 (en) 2000-01-07
DK0894130T3 (da) 2008-01-07
CZ299682B6 (cs) 2008-10-15
EP0894130B1 (en) 2007-12-12
US20090291888A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
HUP9902429A2 (hu) TNF-receptor-asszociált faktor (TRAF) modulátorok előállítása és alkalmazása
WO1996034953A3 (en) Cd16-ii variants
AU3368497A (en) Human dnase i hyperactive variants
EP0853121A3 (en) Human DNase
WO1998055495A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP0278776A3 (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
WO2000015790A3 (en) Leptin induced genes
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
IE871967L (en) Binding-factor-related polypeptides
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
ES8704207A1 (es) Procedimiento para preparar una molecula de adn
AU613583B2 (en) Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity
MX9703364A (es) Peptidos capaces de unirse al dominio sh3 de la proteina gap, secuencias nucleotidicas que codifican para estos peptidos, su preparacion y su uso.
WO2002050111A3 (en) Isolated laminin 10
IE890087L (en) Recombinant human interleukin-1 alpha polypeptides
WO2000053733A3 (en) Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof
EP0780472A3 (en) Stress proteins
DK0811068T3 (da) Humane DNase I varianter
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO1998031796A8 (en) Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C
WO1990014068A3 (en) Anti-ergotypic t cells for the treatment or prevention of autoimmune diseases and methods of use thereof
BG101847A (en) Human dnase i variants